Latest Hycult Biotech news

As of October 1st, 2025, we’re pleased to announce a change in our management structure at Hycult Biotech. Our Managing Director, Ronald de Niet, is stepping back from daily operations to focus on strategy and long-term development as CEO. Marja...

We are happy to introduce our new ELISA kit developed to determine in vitro quantitative C3bBbP levels in serum and plasma samples. The C3 convertase, C3bBbP arises during Alternative Pathway (AP) activation and is an essential factor for proper functioning of...

New Antibody for Detection of the Membrane Attack Complex Figure 1: IHC of Immunohistochemistry (IHC) of C3 glomerulopathy in a kidney biopsy (FFPE tissue) using antibody (HM2443) anti-C5b-9 staining C5b-9 in tissue. The image was kindly provided by Prof. Lubka...

Neurodegenerative diseases pose a significant challenge for individuals and society, and with treatments not always available, there is a critical need for new drugs. Although the precise pathophysiology of these diseases is often poorly understood, studies have shown that complement...

We are happy to introduce to you our new ELISA kits developed to detect human Factor H-related proteins (FHR-2, FHR-3, FHR-4 and FHR-5). The kits were co-developed within the SciFiMed project, a European multi-disciplinary consortium that includes Hycult Biotech and Sanquin...

Bridging Human and NHP Complement Research. At Hycult Biotech, we understand the importance of testing therapeutic agents on non-human primates (NHP) samples in order to get approval to enter clinical phases. That is why we have committed to the following...

We are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to...

Our colleague Erik Toonen shared his experience on how to analyze complement at the Complement-based Drug Development Summit in Boston in September 11-13th, 2023. He showed valuable insights on analyzing complements. For accurate complement analysis, it is important that not...

Upcoming Events 2025 Hycult Biotech regularly participates in, organizes, and supports various congresses. We believe it is crucial to keep up-to-date of the latest advancements in life science and to engage with all stakeholders involved. These events provide us with...

We are happy to introduce our new ELISA (cat.# HK3017) designed to detect human C3d. What sets this assay apart is its utilization of a distinctive neo-epitope capture antibody that selectively targets a specific C3d region of the alpha chain, which...

Introducing a new blocking antibody targeting complement C5, now available for preclinical research! Complement C5 plays a crucial role in many disease processes, and this new antibody offers the option to mimic blocking of terminal complement pathway. But that's not...

With this enhanced partnership, Hycult Biotech is leveraging Bioz' innovative product-specific article recommendations to guide customers in selecting reliable experimentation techniques and products, ultimately saving time and resources. Customers can now access product use-cases on Hycult Biotech's website through Bioz...